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be treated with the TEM technique. The results with this 
procedure are not very different then with the transab-
dominal approach which includes a low anterior resection 
(LAR) and total mesorectal excision (TME) or an abdom-
inoperineal resection (APR)5–9. TEM is not the only recog-
nized technique for local tumor excision. Small and large 
polyps can be removed colonoscopically. This technique is 
reserved only for adenomas and Tis. In that case either 
mucosectomy or loop electroresection is made. The advan-
tages are good visualization and the possibility of resec-
tion in the whole length of the colon and rectum. The dis-
advantages are insuffi ciency of endoscopic instruments 
and also there is a greater possibility of perforation and 
uncontrolled bleeding10,11. Although the classical trans-
anal resection does enable full thickness resection, due to 
poor visualization it’s restricted only to tumors not larger 
Introduction
TEM is an endoscopic procedure and a successful 
method of operating tumors up to 18 cm of the anal verge. 
Although the indications are narrow in relation to the 
transabdominal approach, with this method we can avoid 
major surgery1–4. The technique during its beginnings of 
application was limited primarily to the excision of large 
polyps but thanks to the great upsurge of, in the fi rst place 
neoadjuvant, but also adjuvant chemoradiation the indica-
tion have expanded on early rectal cancer pT1” low risk” 
(G1 and G2). Studies have been made on a larger number 
of patients with pT2 (G1 and G2), pT3, including even pT4 
rectal cancer which have shown that some patients (good 
responders) after neoadjuvant chemoradiation and after 
reaching a lower tumor stage, while being N0 and M0, can 
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A B S T R A C T
TEM is an endoscopic method of operating tumors up to 18 cm of the anal verge. It enables procedures from a simple 
mucosectomy to en-block excisions of the whole thickness of the rectal wall. We present a study in which we evaluated 
surgical morbidity, mortality and recurrence rate of rectal tumors in patients treated with TEM from July 2007, up to the 
end of March 2014. In our Department 129 patients were treated by TEM and 123 of them (74 men and 49 women) had 
rectal tumors: 55 adenomas, 36 cancers in situ (Tis), 15 T1, 9 T2, 4 T3 (3 palliative, and 1 underwent salvage operation) 
and 4 T4 (all palliative) rectal cancers. 6/123 patients were treated with TEM after the fi nding of metachronic recur-
rences that emerged after previously performing major surgery. In 3/123 cases (2.44%) the resection margins were positive. 
The overall local recurrence rate was 19(15.45%) – adenoma 6/55 (10.91%), Tis 4/36(11.11%), T1 0/15(0%), T2 4/9(44.44%), 
T3 1/4(25%), T4 4/4(100%), respectively. In 2 patients the illness was subsequently disseminated, and in 7 patients it was 
widespread at the time of surgery. Nine (7.31%) patients died during follow-up due to disease dissemination. Minor com-
plications occurred in 24 patients (19.51%) whereas we had no major complications and no early postoperative mortality. 
The average postoperative hospital stay is 2.3 days. TEM is a safe and appropriate surgical treatment option for benign 
rectal tumors and for early-stage rectal carcinomas. TEM is also good as a palliative method, and it’s useful for elderly 
and unfi t patients.
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than 3 cm and not deeper than 8 cm of the anal verge12,13. 
Comparing TEM with other techniques of local excision of 
tumors, the advantages are excellent visualization and 
specially angled hand instruments for precise maneuver-
ing within the rectoscope tubes which enables to perform 
procedures from a simple mucosectomy to en-block exci-
sion of the whole thickness of the rectal wall with the re-
section of the pertaining fat tissue. Compared to other 
local resection techniques it has been proven that the 
number of recurrences is signifi cantly lower after TEM14,15.
Although this technique dates from the year 1983., it 
took some time for TEM to rightfully take its place among 
classical tumor resection surgeries. Partially because it 
has a very slow learning curve, and partially, because of 
the unwarrantable fear of insuffi cient radicality of the 
technique. Thanks to the development of magnetic reso-
nance, endoscopic ultrasonography, PET CT and better 
understanding of the behavior of the tumor depending on 
its differentiation, penetration, molecular and genetic 
characteristic, today we are able to determine more exact 
indications and selection of patients which can be oper-
ated with the TEM technique with results which will not 
differentiate from the results of classical operations16–18.
Subjects and Methods:
TEM was introduced in the workmanship of the De-
partment of Digestive Surgery at the Clinical Hospital 
Centre of Rijeka at the end of the year 2007. All patients 
have the same preoperative treatment. The day before 
surgery they are given lighter meals with lots of fl uids. 
The night before surgery an enema is admitted to the pa-
tient as is in the morning of the surgery. All patients pre-
operatively get antibiotic prophylaxis – Metronidazole 500 
mg i.v. and Cefazoline 1.0 g i.v., except patients with Ceph-
alosporins and/or Penicillin allergy who get 160 mg Ga-
ramycin i.v. All patients undergo general anaesthesia. 
Immediately after surgery they begin oral intake of liq-
uids and light food and are mobilized.
Up to the end of March of 2014, 129 patients were oper-
ated with this technique (76 men and 53 women). 123 
patients had tumor of the rectum (74 men and 49 women). 
Average age range is 65.38±11.58. Of the total tumor num-
ber, 55 were adenomas with all degrees of dysplasia, 36 
Tis, 15 T1, 9 T2, 4 T3 (3 palliative, and 1, after the patho-
histological report, underwent salvage LAR with TME) 
and 4 T4 (all palliative) rectal cancers. From 123 patients 
with rectal tumors 6 patients were subjected to TEM be-
cause of metachronic recurrences that have emerged after 
previously performing major surgery for treating colon 
and rectal cancer. Other TEM operations have dealt with 
3 infl ammatory stenosis, 2 stenosis of the anastomosis and 
1 extraction of a foreign object.
Patients that underwent surgery due to adenoma, Tis 
and T1 tumor grade require only regular surgical follow-
up. Patients with tumors graded T2–T4, except surgical, 
also have an oncological follow-up. Regarding oncological 
treatment, 5 of 17 T2–T4 patients were not treated with 
chemoradiation due to patient comorbidity, general poor 
condition or old age. Three of them, whose preoperative 
staging showed T2,N0,M0 rectal cancer, were treated 
with high dose neoadjuvant radiation and chemotherapy 
and underwent TEM 8–10 weeks after the fi nal dose of 
radiation treatment. The remaining 9 patients were sub-
dued to adjuvant chemoradiation.
Data analysis 
Tabular presentation, data entry and processing was 
done in Microsoft Offi ce Excel 2007 (Microsoft)
Results
One hundred and twenty three patients were treated 
by TEM for tumor diseases. In 3 cases (2.44%) the resec-
tion margins were positive (1T3, 1T2, 1Tis). Two patients 
had repeated TEM for biopsy (Tis and T2), and one patient 
with T3 underwent LAR with TME. Including all opera-
tions the recurrence rate was 21 (17.07%). We were pre-
sented with 19(15.45%) local recurrences: adenoma with 
all types of dysplasia 6/55 (10.91%), Tis 4/36 (11.11%), T1 
0/15 (0%), T2 4/9 (44.44%), T3 1/4 (25%), T4 4/4 (100%), 
respectively. In the group of patients where TEM was pre-
formed after previous major surgery the recurrence rate 
was 2/6 (33.33%) – they both were distant metastasis 
which we tend to correlate with primary tumor dissemina-
tion because the local fi ndings were all adenomas. Re-
curences from the adenoma and Tis group were all re-
solved with repeated TEM procedure. In the T2 group 
repeated TEM was indicated in 2 patients, while LAR 
with TME was indicated in one patient and in one patient 
APR was done. In one patient preoperative staging showed 
that we were dealing with T1N0M0 carcinoma but the 
fi nal pathohistological result was a pT3 tumor so he un-
derwent salvage surgery in which classical LAR with 
TME was done. He didn’t present any recurrences after 
surgery. In the T3 and T4 group we did 7 palliative proce-
dures because of liver metastasis which we didn’t count as 
recurrences. One T3 group patient and all T4 group pa-
tients presented asymptomatic local recurrences in the 
terminal phase of the illness and the decision was not to 
operate further. Considering all patients up till today, 
9/123 (7.32%) has died due to the consequence of disease 
dissemination. Taking into account the fact that these 
were patients with T2–T4 cancers, the real percentage is 
9/23 (39.13%). These concerns the patients in whom the 
illness was disseminated before the procedure and 2 cases 
from the group of patients with disseminated disease that 
previously underwent major surgery due to colorectal ma-
lignancy. The total survival rate is 92.68%, and the sur-
vival rate in the T2–T4 group is 60.87%. The follow-up 
median of all patients is 42 months (1–71 months) (Table 
1). In these seven years of experience with TEM we had 
no early postoperative mortality and the number of com-
plications was minimal. We had 2 suture disruptions that 
did not require further intervention, 11 patients had high 
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TABLE 1
OUR RESULTS IN 123 PATIENTS WITH TUMOROUS DISEASE TREATED WITH TEM

















adenoma 49 6(12.24%) TEM 100%
Metachronic or 
synchronic adenoma
After major surgery 
(T2–T4)
  6 Adjuvant after 
major surgery
0 2(33.33%) 33.33% 48
Σ adenomas 55 6(10.91%) 2(3.64%) 96.36% 48
Tis 36 4(11.11%) 0 TEM 100% 32
T1 15 0 0 100% 33















Σ T2N0M0   9 4(44.44%) 0 100% 47
T3 N0 M0   1 adjuvant 0 0 LAR 100%




1(50%) (3 M1)* 0% 19
Σ T3   4 1(25%) (3 M1)* 25% 19




4(100%) (4 M1)* 0% 15
Σ 1230 19(15.45%) 2(1.63%) 92.68% 42
Σ T2–T4 23 9(39.13%) 2(8.70%) 60.87% 40
TEM – transanal endoscopic microsurgery; LAR – low anterior resection; APR – abdominoperineal resection; pal – palliative surgery; * – 




Fever (fi rst two post surgery days) 11
Fever (6 post surgery days)   1
Bleeding   0
Suture disruption   2
Mortality   0
Dysuric diffi culties   7
Transitory fecal incontinence   3
Total complications 24 (19.51%)
fever in the fi rst 2 postoperative days, one patient had fe-
ver during 6 days after surgery. Seven patients had dys-
uric diffi culties and three had transitory fecal inconti-
nence (Table 2). Over 80% of patients did not have any 
demands regarding analgesia. None of the patients re-
ceived blood transfusion. The average postoperative hos-
pital stay is 2.3 days.
Discussion and Conclusion
With adequately nominated indications, TEM is a 
method of choice for treating large adenomas, carcinomas 
in situ, but also cancer pT1. There are controversy regard-
ing the indications for TEM in pT2 cancers. It has been 
proven that with pre-procedural downstaging of rectal 
carcinoma there are higher survival rates and fewer re-
currences. If these tumors are larger than 3.5 centimeters 
or „high risk” (poorly or undifferentiated adenocarcinoma 
with lymphatic invasion), the recommendation is to submit 
the patient to open or laparoscopic resection4–8. TEM is 
also good as a palliative method, or in patients that have 
high operational risk. Postoperative course is in general 
without pain, the hospital stay is short, and expenses (ex-
cluding the initial investment) are low. In the end, the 
results of treating patients with good indications with 
TEM are in accordance with the results of treating the 
disease with classical surgery, but they are better than 
the results of treating them with methods of transanal 
excision or endoscopic mucosal resection14.
Thanks to the better understanding of the pathophys-
iology of tumors, new achievements and acquisitions in 
oncological treatment and exceeding improvements in di-
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agnostics, TEM, as a minimally invasive technique with 
a small number of complications, is fl aring up. We can now 
perform more adequate preoperative staging and subse-
quent follow up of patients which lead to an expansion of 
indications for the treatment. It is encouraging that the 
results in TEM treated patients are in comparison with 
classical treatment results4,16–18. Although this technique 
has its limitations, TEM is fi nally taking its earned place 
in the surgical treatment of rectal tumors.
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TRANSANALNA ENDOSKOPSKA MIKROKIRURGIJA (TEM) – ALTERNATIVA ILI METODA IZBORA 
U LIJEČENJU TUMORA REKTUMA KOD DOBRO ODABRANIH BOLESNIKA?
S A Ž E T A K
TEM je endoskopska medoda kojom se mogu operirati rektalni tumori do 18 cm od anokutane granice, s mogućnostima, 
od jednostavne mukozektomije do ekscizije cijele debljine stijenke rektuma. Ovim radom predstavljamo studiju kojom 
ćemo evaluirati morbiditet, mortalitet te recidive kod bolesnika s tumorima rektuma koji su operirani TEM-om od srpnja 
2007. do ožujka 2014. godine. Na našem Zavodu je TEM tehnikom operirano 129 bolesnika. Od toga 123 bolesnika (74 
muškaraca i 49 žena) zbog tumora rektuma. Bilo je 55 adenoma, 36 karcinoma in situ (Tis), 15 T1, 9 T2, 4 T3 (3 pali-
jacijska i 1 podvrgnut klasičnoj prednjoj resekciji rektuma po dobivenom patohistološkom nalazu) te 4 T4 (svi palijaci-
jski) karcinoma rektuma. 6/123 bolesnika je imalo metakrone recidive u rektumu po ranije učinjenim klasičnim 
zahvatima.U 3/123 slučajeva (2,44%) resekcijski rubovi su bili pozitivni. Ukupan broj lokalnih recidiva je bio 19 (15,54%) 
– adenomi 6/55 (10,91%), Tis 4/36 (11,11%), pT1 0/15 (0%), pT2 4/9 (44,44%), pT3 1/4 (25%), pT4 4/4 (100%). U 2 bolesn-
ika se bolest naknadno proširila, a kod 7 bolesnika je bolest već bila proširena. Devet (7,31%) bolesnika je umrlo tijekom 
dosadašnjeg praćenja zbog proširenja bolesti. Imali smo 24 bolesnika (19,51%) s manjim komplikacijama dok većih kom-
plikacija nije bilo, kao niti rane poslijeoperacijske smrtnosti. Prosijek poslijeoperacijskog ležanja je bio 2,3 dana. Zah-
vati učinjeni TEM-om su sigurni i primjereni za liječenje dobročudnih tumora rektuma, ali i ranog stadija karcinoma. 
TEM je također dobra metoda u palijacijskim zahvatima te kod starih i iznemoglih bolesnika.
